January 30, 2017 08:43 AM EST
R&D

Mi­cro­cap biotech Ocera craters on a PhI­Ib fail­ure for he­pat­ic en­cephalopa­thy

John Carroll

Editor & Founder

Ocera $OCRX has joined the grow­ing line­up of mi­cro­cap biotechs to ex­pe­ri­ence the crush­ing ef­fect of a clin­i­cal set­back. The biotech an­nounced that its lead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times